News

The STRIVE trial is designed to evaluate the safety and efficacy of the vaccine to determine if it prevents postoperative invasive S. aureus infections in patients undergoing elective

The closing of the stock purchase transaction is subject to customary closing conditions for a transaction of this nature and approval of the Toronto Stock Exchange. Under the

"We are excited to collaborate with UCSF, a world-renowned academic research institution," said Jonathan Lim, M.D., Chairman and CEO of Ignyta. "The focus on melanoma in this study

RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. The MAP US study is the first

FCS is a rare genetic disease characterized by extremely high triglyceride levels and risk of pancreatitis. In a Phase 2 study published in the NEJM in December 2014,

The company’s therapy, called 514G3, was developed from a human donor with natural antibodies effective at neutralizing MRSA and non-MRSA forms of S. aureus. According to the company,

CAT-1004 inhibits activated NF-kB, a protein that coordinates cellular response to muscular damage, stress and inflammation and plays a major role in muscle health. DMD involves progressive muscle

Acebilustat, a once-daily oral drug candidate, is currently being evaluated for the treatment of inflammatory diseases. The drug is a new small molecule inhibitor of Leukotriene A4 Hydrolase

The NDA is based on the results of a large, multicenter, open-label, randomized, Phase III trial that examined the repeated use of Amphora gel compared to a vaginal